Former Bristol Myers Squibb, Goldman Sachs,
and Barclays executive brings deep expertise in corporate strategy,
partnership development, public and private financial markets, and
management as the organization evolves its leadership and
investment strategy
Appointment signals plans to capitalize on
previous success and maximize impact by expanding equity
investments and partnerships with venture capital, large biopharma,
and key foundations with a proven team leader
and dealmaker
BOSTON, Jan. 8, 2025
/PRNewswire/ -- The T1D Fund, an impact investment fund with a
focus on accelerating life-changing solutions to treat, prevent,
and cure type 1 diabetes (T1D), today announced it appointed
Elizabeth Mily as Chief Executive
Officer. With more than 30 years of pharma, healthcare investment
banking, and strategic leadership experience, Mily will leverage
her mission-driven commitment to spearheading the next chapter of
the Fund, guiding continued deployment of resources and supporting
a comprehensive approach to curing type 1 diabetes. Under her
leadership, the T1D Fund expects to build on its current momentum,
growing its investment team and expanding strategic partnerships
with an eye toward building an ecosystem for delivering new
therapies. As the T1D Fund's lead public ambassador, Mily will work
to elevate awareness of and investment in leading research,
innovation, and the need for cures for type 1 diabetes.
"Elizabeth brings a bold strategic vision to the T1D Fund during
an exciting period of our evolution. She is the ideal choice to
lead the next chapter as we identify and invest in cutting-edge
approaches for treating type 1 diabetes," said Tim Clark, Chair of the Board of Directors at
the T1D Fund.
Mily joins the T1D Fund after most recently serving as Executive
Vice President, Strategy & Business Development, at Bristol
Myers Squibb, where she oversaw the company strategy and approach
to sourcing external innovation, including all business development
activities, strategic partnerships, alliance management, mergers
and acquisitions, and the company's broad equity investing
portfolio. Previously, she held senior roles at Barclays, Thermo
Fisher Scientific, and Goldman, Sachs & Co., where she led
strategy and transactions for the healthcare, life sciences, and
biopharma sectors. Mily currently serves on the Board of Solventum
Corporation (NYSE: SOLV), where she sits on the Audit and Quality,
Science & Technology Committees; she also serves on the Board
of Ampersand Biomedicines, a private Flagship Pioneering portfolio
company.
"The T1D Fund's unique position as an impact investor enables it
to go beyond capital deployment to proactively work with biopharma
to bring forward innovative therapies with the potential to
translate to transformative cures," said Mily. "As someone who
knows first-hand the serious impacts the disease has on individuals
and their loved ones, I am eager to build upon the team's
meaningful work and partnerships to propel treatments that can
improve the lives of those with type 1 diabetes."
"Elizabeth's wealth of industry knowledge will be instrumental
in the T1D Fund's ability to serve as a true biopharma
partner—capitalizing on unique opportunities and directing market
attention to develop treatments for patients with type 1 diabetes,"
said David Panzirer, Trustee of The
Leona M. and Harry B. Helmsley Charitable Trust. "Leveraging its
deep relationships with Helmsley Charitable Trust and Breakthrough
T1D alongside Mily, the Fund is well-positioned to successfully
drive a multitude of breakthroughs to market readiness."
About the T1D Fund: A Breakthrough T1D Venture,
LLC
The T1D Fund is an impact investment fund accelerating
life-changing solutions to treat, prevent, and ultimately cure type
1 diabetes (T1D). Launched in December
2016, it is the first scaled, mission-driven venture impact
fund established to catalyze the development of T1D cure-oriented
therapies through equity investments in partnership with additional
sources of capital, including venture capital, corporations, and
foundations. T1D Fund is managed by a dedicated team of investment
professionals that invest in innovative approaches and novel
mechanisms with curative potential in type 1 diabetes. Its focus is
strategically aligned with Breakthrough T1D (formerly JDRF) and the
Helmsley Charitable Trust, the leading global organizations funding
T1D research and working to change the lives of those who are
affected by T1D. Learn more at t1dfund.org. Follow the T1D Fund on
Linkedin.
Media Contact
Lia
Dangelico
lia.dangelico@deerfieldgroup.com
540-303-0180
View original content to download
multimedia:https://www.prnewswire.com/news-releases/the-t1d-fund-appoints-industry-veteran-elizabeth-mily-as-ceo-to-accelerate-development-of-type-1-diabetes-cures-through-impact-investing-302345016.html
SOURCE The T1D Fund
